VIAL
Compound comparison

CJC-1295 vs Sermorelin

CJC-1295 and Sermorelin are both peptide compounds evaluated on Vial: CJC-1295 is available as a compounded preparation with clinical-trial evidence, and Sermorelin is available as a compounded preparation with clinical-trial evidence, offered by 16 and 26 verified providers respectively.

Vial summary · compiled from public records

At a glance

CJC-1295

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
16providers on Vial →

Sermorelin

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
26providers on Vial →

Side by side

FieldCJC-1295Sermorelin
CategoryPeptidePeptide
Brand names
FDA / legal statusCompoundableCompoundable
Evidence tierClinical TrialsClinical Trials
Administration routeSubcutaneousSubcutaneous
Compounding accessAvailable through 503A and 503B compounding pharmaciesAvailable through 503A and 503B compounding pharmacies
Providers on Vial16 listed26 listed
Typical price band$$ to $$$$ to $$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About CJC-1295

A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.

About Sermorelin

A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →